A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Background: Inactivation of the VHL gene leading to aberrant HIF2α activity is nearly universal in clear cell renal cell carcinoma (ccRCC). NKT2152 is a novel, potent, selective orally available HIF2α inhibitor optimized for enhanced PK exposure and sustained target inhibition which has demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonasch, Eric, Hauke, Ralph, Falchook, Gerald, Logan, Theodore, Gordon, Michael, Hall, Evan, Schuch, Brian, Bilen, Mehmet A, Naqash, Abdul, Zakaharia, Yousef, Ryan, Christopher W, Lally, Satwant, Xiao, Jim, Zimmerman, Zachary, Srinivasan, Ramaprasad, Choueiri, Toni K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445566/
http://dx.doi.org/10.1093/oncolo/oyad216.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445566/
http://dx.doi.org/10.1093/oncolo/oyad216.019

Ejemplares similares